How to Get Alprostadil (Caverject/MUSE) in Oregon

What alprostadil is and why it matters for Oregon patients

Alprostadil is a synthetic prostaglandin E1 (PGE1) that relaxes smooth muscle and dilates penile arteries, producing an erection within 5 to 20 minutes of administration. It is available as Caverject (intracavernosal injection, Pfizer) and as MUSE (medicated urethral system for erection, a soft suppository). Oregon men who have not responded to sildenafil or tadalafil, or who cannot take PDE5 inhibitors due to nitrate use or cardiovascular contraindications, are the primary candidates.

The landmark Linet et al. trial published in the New England Journal of Medicine (N=683 men with erectile dysfunction of varied etiology) found that 87% of men who received home intracavernosal alprostadil achieved erections sufficient for intercourse, compared with 17% in the placebo group (P<0.001). [1] That trial established the efficacy threshold that FDA used when granting approval for Caverject in 1995. [2] Separate dose-titration data from the same period confirmed that a starting dose of 2.5 mcg, escalated in 2.5 mcg steps under clinical observation, minimizes the risk of prolonged erection (priapism). [1]

For MUSE, a multicenter trial (N=1,511) published in the New England Journal of Medicine showed that 64.9% of at-home administrations resulted in an erection sufficient for intercourse versus 18.6% with placebo. [3] The urethral route carries a lower systemic absorption and a slightly reduced efficacy profile compared with injection, which makes it a reasonable second choice for men who decline self-injection. [3]

Oregon follows federal FDA guidance on both formulations and imposes no additional state-level scheduling restrictions on alprostadil beyond standard prescription requirements. [4]

How to get an alprostadil prescription in Oregon

Any Oregon-licensed MD, DO, nurse practitioner (NP), or physician assistant (PA) with prescriptive authority may write an alprostadil prescription. Oregon revised statutes grant full prescriptive authority to NPs (ORS 678.375) and PAs (ORS 677.505), so patients are not limited to urologists or primary-care physicians. [4]

The practical pathway runs as follows. A patient schedules a consultation, either in person or via a telehealth platform licensed in Oregon. The clinician reviews the patient's sexual health history, current medications, and cardiovascular risk. If alprostadil is appropriate, the provider writes a prescription specifying the formulation (Caverject or MUSE), the starting dose, and the maximum number of doses per week (the FDA label caps Caverject use at no more than three times weekly and no more than once in 24 hours [2]).

Oregon telehealth law (ORS 442.015 and OAR 847-015-0000 through 847-015-0050) allows synchronous audio-video consultations to establish the prescriber-patient relationship needed for a new prescription. [4] A clinician conducting a telehealth visit must have access to the patient's relevant history and must document a clinical exam by review of submitted information; Oregon does not require an in-person physical examination before alprostadil prescribing specifically. The Oregon Medical Board confirms this interpretation in its telehealth guidance. [4]

Because intracavernosal injection technique requires training, most prescribers schedule a brief in-office or telehealth-guided training session before the patient self-injects at home. That session can occur on the same day as the initial consult.

What labs are required before starting alprostadil in Oregon

Alprostadil does not require the same extensive metabolic panel that some systemic hormonal therapies demand, but responsible prescribing includes a targeted workup. The American Urological Association (AUA) guideline on erectile dysfunction (2018, amended 2024) recommends evaluating cardiovascular risk, hormonal status, and glycemic control before prescribing any ED therapy. [5]

Standard baseline labs for alprostadil candidates typically include the following. Fasting glucose and HbA1c identify uncontrolled diabetes, which both causes ED and slows wound healing at injection sites. Total testosterone (morning draw, two measurements) rules out hypogonadism as a primary or contributing cause, because testosterone-deficient men may have a blunted response to alprostadil without concurrent testosterone replacement. [5] A lipid panel and blood pressure measurement complete cardiovascular risk stratification per the Princeton Consensus III, which classifies patients into low, intermediate, and high cardiac risk categories before any ED treatment. [6] Complete blood count and basic metabolic panel are ordered selectively based on comorbidities.

Labs are usually drawn at a local Quest, LabCorp, or Oregon Health and Science University (OHSU) outpatient lab. Telehealth providers that service Oregon typically send electronic requisitions to a draw site near the patient's zip code. Results return in 24 to 72 hours, after which the prescriber clears the patient for the prescription.

Men with known penile anatomical abnormalities (Peyronie's disease, significant curvature) should also undergo a duplex Doppler ultrasound of the penile vasculature before intracavernosal injection, since injection into fibrotic tissue carries a higher complication risk. [5]

Telehealth platforms prescribing alprostadil in Oregon

Oregon permits telehealth prescribing of alprostadil without an initial in-person visit, provided the prescriber completes a synchronous audio-video encounter and documents adequate clinical assessment. Several national telehealth platforms maintain Oregon-licensed clinicians and can serve state residents.

When evaluating a telehealth provider for alprostadil in Oregon, consider four criteria: (1) the platform holds prescriber licenses in Oregon for at least one MD or DO who can supervise NP or PA prescribers under Oregon collaborative practice rules; (2) the intake form explicitly screens for priapism history, sickle-cell disease, and current anticoagulant use, all of which modify alprostadil risk; (3) the platform offers a live training session (video or in-person) for injection technique rather than sending a Caverject autoinjector kit with no guidance; and (4) the platform can route the prescription to a licensed Oregon pharmacy or licensed 503A compounder.

Hormone-specialty telehealth services that already manage testosterone replacement therapy (TRT) for Oregon men are well positioned to also prescribe alprostadil, because the patient's cardiovascular and hormonal baseline is already established. The FDA label for Caverject notes that hypogonadal men may need concurrent testosterone optimization for the best response. [2] A urologist at OHSU or a community urology practice remains the gold standard for complex cases, including post-prostatectomy ED, spinal cord injury-related ED, or ED refractory to alprostadil monotherapy.

Oregon pharmacy access: retail, mail-order, and 503A compounding

Retail and mail-order pharmacies. Caverject (alprostadil 10 mcg and 20 mcg powder for injection) and MUSE suppositories (125, 250, 500, and 1 to 000 mcg) are FDA-approved brand products. They are stocked at larger retail chains including Walgreens and Fred Meyer in Oregon, though rural pharmacies may require a 24- to 48-hour special order. GoodRx and similar discount programs reduce out-of-pocket cost for uninsured patients; Caverject 20 mcg (6-pack) lists at roughly $550 to $750 cash price, while MUSE 500 mcg (6-pack) runs approximately $400 to $600 depending on the pharmacy. [2]

Mail-order is available through Oregon Medicaid-preferred pharmacies and through most commercial PBM mail-order programs. Pfizer's Caverject patient-assistance program (PAP) covers eligible patients who meet income thresholds. [2]

503A compounding pharmacies. Oregon allows licensed 503A pharmacy compounding of alprostadil for individual patients when a valid patient-specific prescription exists and when a commercially available product is not suitable for the patient (for example, a patient needing a dose or concentration not available in the brand product, such as a low-dose 1.25 mcg vial for dose titration). [4] The Oregon Board of Pharmacy regulates 503A pharmacies under ORS Chapter 689 and OAR 855-019. [4] Compounded alprostadil is commonly prepared as a multi-dose vial in concentrations from 10 to 500 mcg/mL in bacteriostatic water, or as an alprostadil/papaverine/phentolamine tri-mix formulation for patients with inadequate mono-therapy response.

503A compounders in Oregon cannot produce anticipatory batches for office stock; every vial must correspond to a named patient prescription. Prescribers who prefer compounded formulations should confirm the compounder holds current Oregon Board of Pharmacy licensure before routing the prescription. Interstate 503A shipments into Oregon from out-of-state compounders are permitted only when the compounding pharmacy is licensed in Oregon or complies with OAR 855-041. [4]

Oregon Medicaid (OHP) prior authorization for alprostadil

Oregon Health Plan (OHP) covers alprostadil for refractory erectile dysfunction with prior authorization. The Oregon Pharmacy and Therapeutics Committee places alprostadil on the preferred drug list (PDL) under the urological agents category, subject to PA criteria that mirror clinical guidelines. [7]

Standard PA documentation requirements include the following items. The clinician must certify that the patient has a diagnosis of erectile dysfunction (ICD-10 N52.x) documented in the medical record. The PA form requires evidence of trial and failure of at least one oral PDE5 inhibitor (sildenafil, tadalafil, vardenafil, or avanafil) at an adequate dose and duration, typically defined as four or more attempts at the maximum tolerated dose. Contraindications to PDE5 inhibitors (concurrent nitrate therapy, severe hypotension, or documented drug allergy) also satisfy the trial-and-failure requirement without a prior PDE5 inhibitor trial. [7]

Oregon Medicaid PA requests are submitted through the OHP pharmacy PA portal or via fax to the Oregon Health Authority designated PA unit. Approval turnaround for non-urgent requests is typically three to five business days. Urgent PA requests, where the clinician documents clinical urgency, are processed within 24 hours under OHP rules. [7]

Commercial insurance PA in Oregon follows insurer-specific criteria, but most Oregon-licensed commercial plans (PacificSource, Moda Health, Regence, Providence Health Plan) use criteria similar to OHP, requiring documented PDE5 inhibitor failure or contraindication. A urologist or prescribing NP can complete the PA paperwork; many telehealth platforms also offer PA support staff who draft the letter on the clinician's behalf.

The AUA erectile dysfunction guideline states directly: "Alprostadil (intracavernosal or intraurethral) is recommended as second-line therapy for men who fail or are intolerant of oral PDE5 inhibitors." [5] That language from a named guideline is the single most useful quote to include in a PA letter for Oregon commercial plans.

Dosing, titration, and safety monitoring in Oregon clinical practice

Caverject is titrated under clinical supervision. The FDA-approved starting dose is 2.5 mcg for men with neurogenic ED (post-prostatectomy, spinal cord injury, diabetic neuropathy) and 5 mcg for men with vasculogenic ED. [2] The clinician increases the dose in 2.5 to 5 mcg increments during office or telehealth-supervised sessions until the patient achieves an erection lasting 60 minutes or less. The dose that produces a 60-minute or shorter erection becomes the home-use dose. [2]

MUSE is initiated at 125 or 250 mcg in the office or clinic, with the patient observed for at least 30 minutes after administration to screen for symptomatic hypotension and to confirm absence of urethral bleeding. The FDA label for MUSE requires this initial in-office trial before home use. [2] After a satisfactory office trial, patients administer MUSE at home at the confirmed effective dose.

Priapism risk. Erections lasting longer than four hours (priapism) require emergency intervention. The Massachusetts Male Aging Study and post-marketing surveillance data estimate priapism incidence with intracavernosal alprostadil at approximately 1% per injection episode. [8] Oregon patients should be counseled to go to an emergency department if erection persists beyond four hours, where phenylephrine intracavernosal injection is the first-line reversal agent per AUA guidance. [5]

Penile fibrosis. Repeated injection at the same site may cause fibrotic nodules. Rotating injection sites along the lateral aspect of the corpus cavernosum reduces this risk. The FDA label reports fibrosis in approximately 3% of men using Caverject long-term. [2]

Cardiovascular monitoring. Because alprostadil produces systemic vasodilation at higher doses, blood pressure should be rechecked at the first follow-up visit (typically four to eight weeks after initiation). Men on alpha-blockers (tamsulosin, doxazosin) or antihypertensives should begin at the lowest alprostadil dose and have blood pressure measured after the first in-office dose. [2]

The Endocrine Society clinical practice guideline on male hypogonadism notes that men receiving testosterone replacement who also use alprostadil should have hematocrit monitored every three to six months, since polycythemia secondary to testosterone raises thromboembolic risk and may potentiate priapism. [9]

Transferring an existing alprostadil prescription to Oregon

Oregon pharmacies accept valid prescriptions written by any DEA-registered, state-licensed prescriber. An alprostadil prescription written by a California or Washington urologist is transferable to an Oregon pharmacy, provided Oregon pharmacy law transfer rules are met (ORS 689.515). [4] For controlled substances this process is more restricted, but alprostadil is not a scheduled controlled substance, making transfer straightforward.

Patients relocating to Oregon who have a valid alprostadil prescription from another state should contact their new Oregon-based pharmacy and ask the pharmacist to contact the original dispensing pharmacy for a transfer. Electronic prescription transfers between states are accepted under Oregon pharmacy interoperability rules. [4] If the original prescription was written by a clinician no longer licensed in Oregon, the patient needs a new evaluation from an Oregon-licensed provider, which can be completed via telehealth on the same day.

Expected timeline from consult to first dose in Oregon

Most Oregon patients move from initial telehealth consult to first home dose within five to 14 days. Day one involves the telehealth video visit and lab requisition. Labs return in one to three days. The prescriber reviews results and, if appropriate, sends the electronic prescription to the pharmacy. Retail pharmacies in Portland, Eugene, Salem, and Bend typically dispense Caverject or MUSE within 24 hours of receiving the prescription; rural pharmacies may require two to three additional days for special order. Mail-order pharmacies ship within three to five business days. 503A compounding pharmacies generally prepare and ship within three to seven business days after receiving the prescription.

The mandatory MUSE in-office or supervised observation visit adds one scheduling step for MUSE users, but this can often be handled via a telehealth-supervised self-administration with the patient in a safe home setting when in-person access is limited, at the prescriber's clinical discretion. [2]

Total elapsed time from deciding to pursue alprostadil to administering the first home dose is therefore approximately one week for most urban Oregon residents and up to two weeks for patients in rural areas or those requiring PA approval through OHP.